CXO (Pharmaceutical outsourcing) sector, which had a sharp decline in share price, has now ushered in a new turnaround. Statistics show that yesterday, the pharmaceutical outsourcing sector represented by Yaoming biology, Asymchem Laboratories (Tianjin) Co.Ltd(002821) , Pharmaron Beijing Co.Ltd(300759) rose collectively. At the same time, the giants of the industry have also shown beautiful transcripts.
“The prosperity of the pharmaceutical outsourcing track is closely related to the R & D investment of innovative drugs.” Bao Jingang, a researcher at private placement paipai.com, told the Securities Daily that since 2021, pharmaceutical stocks in the secondary market, especially innovative drugs, have made a large correction. The market is generally worried about the decline in the rate of return on investment in innovative drugs in China. Superimposed on the decline in the amount of investment and financing in the primary market of the biomedical industry in the third quarter, the market expectation that investors’ enthusiasm for investment in innovative drugs has decreased has increased. However, in the fourth quarter of 2021 and the first quarter of 2022, the investment in the primary market of the track returned to a high level, and the logic of industrial transfer to China was not destroyed. Therefore, it is expected that the pharmaceutical outsourcing industry is expected to continue its high momentum in 2022.
Data show that since August 5, 2021, as of February 15, 2022, Wuxi Apptec Co.Ltd(603259) , Pharmaron Beijing Co.Ltd(300759) share prices have fallen by more than 40%. Since December 2021, the share price of Asymchem Laboratories (Tianjin) Co.Ltd(002821) has fallen by 40% as of February 15.
Despite the sluggish stock price performance, listed companies in the pharmaceutical outsourcing industry have handed over beautiful transcripts.
On February 16, Wuxi Apptec Co.Ltd(603259) released a performance express, which said that the operating revenue in 2021 was 22.902 billion yuan, a year-on-year increase of 38.5%; The net profit attributable to the parent company was 5.097 billion yuan, a year-on-year increase of 72.19%.
According to the performance forecast released by Joinn Laboratories (China) Co.Ltd(603127) , the net profit attributable to shareholders of listed companies is expected to range from 542.7902 million yuan to 574.2916 million yuan in 2021, with a year-on-year increase range of 72.3% to 82.3%.
According to the performance forecast released by Asymchem Laboratories (Tianjin) Co.Ltd(002821) , the revenue range is expected to be 4.505 billion yuan to 4.662 billion yuan in 2021, with a year-on-year increase range of 43% to 48%. Among them, in the fourth quarter of 2021, the revenue range was 1.675 billion yuan to 1.73 billion yuan, with a year-on-year increase range of 57% to 62%. Excluding the impact of exchange rate, the year-on-year growth range of the company’s annual and fourth quarter revenue was 52% to 57% and 62% to 67% respectively.
Li Yifeng, chief researcher of Guangzhou roundstone investment pharmaceutical industry, told the Securities Daily that there was no obvious inflection point change in the prosperity of the pharmaceutical outsourcing industry in 2022. Considering the “engineer bonus” and “cost advantage” of the supply chain of this track in China, The prosperity indicators of China’s R & D expenditure (the accepted varieties of innovative drugs ind and China’s primary investment and financing) have not changed, and the judgment of the high outlook of the China Meheco Group Co.Ltd(600056) outsourcing industry is still maintained.
Despite the bright overall performance last year, the pharmaceutical outsourcing industry is still facing phased challenges. Wuxi Apptec Co.Ltd(603259) in the 2021 performance express, it is said that the business of China new drug R & D Service Department (wuxiddsu) will be upgraded iteratively in 2022 to meet customers’ higher requirements for China’s new drug R & D services, and the revenue is expected to decline to a certain extent.
“There are three main factors affecting the reduction of investment in innovative drugs in China: first, the breaking of innovative drug enterprises listed in Hong Kong stocks has aroused market concerns; second, the impact of the new deal of the industry; third, the sea strategy of innovative drug enterprises has been blocked.” Li Yifeng said.
